Clinical trial protocol to evaluate the efficacy of cefixime in the treatment of early syphilis

Shivani N Mehta, Chrysovalantis Stafylis, David M Tellalian, Pamela L Burian, Cliff M Okada, Carl E Millner, Christopher M Mejia, Jeffrey D Klausner, Shivani N Mehta, Chrysovalantis Stafylis, David M Tellalian, Pamela L Burian, Cliff M Okada, Carl E Millner, Christopher M Mejia, Jeffrey D Klausner

Abstract

Background: Syphilis rates have been increasing both in the USA and internationally with incidence higher among men-who-have-sex-with-men and people living with human immunodeficiency virus (HIV) infection. Currently, benzathine penicillin is the recommended treatment for syphilis in all patients. Global shortages and cost increases in benzathine penicillin call for alternative treatment options. This study evaluates the efficacy of oral cefixime for the treatment of early syphilis.

Methods: We are conducting a randomized, multisite, open-label, non-comparative clinical trial in Los Angeles and Oakland, CA. Eligible participants are ≥ 18 years old, with primary, secondary, or early latent syphilis (rapid plasma reagin [RPR] titer ≥ 1:8). Patients with HIV infection must have a viral load ≤ 200 copies/mL and CD4+ T cell count ≥ 350 cells/μL during the past 6 months. Participants are randomized to receive either 2.4 M IU benzathine penicillin G intramuscularly once or cefixime 400 mg orally twice a day for 10 days. Participants return at 3, 6, and 12 months post-treatment for follow-up RPR serological testing. The primary outcome is the proportion of participants who achieve ≥ 4-fold RPR titer decrease at 3 or 6 months post-treatment.

Discussion: Clinical trials evaluating the efficacy of alternative antibiotics to penicillin are urgently needed.

Trial registration: Clinicaltrials.gov NCT03660488 . Registered on 4 September 2018.

Keywords: Cefixime; Clinical trial; Early syphilis; Penicillin; Syphilis; Treponema pallidum.

Figures

Fig. 1
Fig. 1
Participant enrolment and follow-up schedule

References

    1. . Cefixime for alternative syphilis treatment. Bethesda: National Library of Medicine (US); 2018.
    1. Braxton J, Grey J, Harvey A, Kidd S, Presley RJ, Ramirez V, et al. Syphilis surveillance supplement 2013–2017 for sexually transmitted disease surveillance 2017. 2019.
    1. Kojima N, Klausner JD. An update on the global epidemiology of syphilis. Curr Epidemiol Rep. 2018;5(1):24–38. doi: 10.1007/s40471-018-0138-z.
    1. World Health Organization . WHO guidelines for the treatment of Treponema pallidum (syphilis) 2016.
    1. Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014;312(18):1905–1917. doi: 10.1001/jama.2014.13259.
    1. Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;42(6):e45–ee9. doi: 10.1086/500406.
    1. Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med. 2008;121(10):903–908. doi: 10.1016/j.amjmed.2008.04.042.
    1. Centers for Disease Control and Prevention . 2015 STD Treatment Guidelines. 2015.
    1. Roberts CP, Raich A, Stafylis C, Klausner JD. Alternative treatments for syphilis during pregnancy. Sex Transm Dis. 2019;46(10):637–640. doi: 10.1097/OLQ.0000000000001050.
    1. Nurse-Findlay S, Taylor MM, Savage M, Mello MB, Saliyou S, Lavayen M, et al. Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: an evaluation from multi-country surveys and stakeholder interviews. PLoS Med. 2017;14(12):e1002473. doi: 10.1371/journal.pmed.1002473.
    1. Taylor MM, Zhang X, Nurse-Findlay S, Hedman L, Kiarie J. The amount of penicillin needed to prevent mother-to-child transmission of syphilis. Bull World Health Organ. 2016;94(8):559. doi: 10.2471/BLT.16.173310.
    1. World Health Organization . Shortages of benzathine penicillin. How big is the problem? And why it matters. 2017.
    1. Liang Z, Chen Y-P, Yang C-S, Guo W, Jiang X-X, Xu X-F, et al. Meta-analysis of ceftriaxone compared with penicillin for the treatment of syphilis. Int J Antimicrob Agents. 2016;47(1):6–11. doi: 10.1016/j.ijantimicag.2015.10.020.
    1. Suprax® (cefixime) Tablets USP, 400 mg; [package insert]. Baltimore: Lupin Pharmaceuticals, Inc; 2012.
    1. Faulkner R, Bohaychuk W, Haynes J, Desjardins R, Yacobi A, Silber BM. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol. 1988;34(5):525–528. doi: 10.1007/BF01046715.
    1. Faulkner R, Fernandez P, Lawrence G, Sia L, Falkowski A, Weiss A, et al. Absolute bioavailability of cefixime in man. J Clin Pharmacol. 1988;28(8):700–706. doi: 10.1002/j.1552-4604.1988.tb03203.x.
    1. Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, et al. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. Pharmacotherapy. 1997;17(1):121–125.
    1. Schatz BS, Karavokiros KT, Taeubel MA, Itokazu GS. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Ann Pharmacother. 1996;30(3):258–268. doi: 10.1177/106002809603000310.
    1. Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittel-Forschung. 2008;58(2):97–100.
    1. Barbee LA, Nayak SU, Blumer JL, O'Riordan MA, Gray W, Zenilman JM, et al. A Phase 1 pharmacokinetic and safety study of extended-duration, high-dose cefixime for cephalosporin-resistant Neisseria gonorrhoeae in the pharynx. Sex Transm Dis. 2018;45(10):677–683. doi: 10.1097/OLQ.0000000000000844.
    1. Rafal'skiĭ VV, Kozyrev I, Gustovarova TA, Khlybova SV, Novoselova AV, Filippenko NG, Likhikh DG. The efficacy and safety of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women: a randomized, prospective, multicenter study. Urologiia (Moscow, Russia: 1999). 2013(5):24–6.
    1. Arlington Scientific Inc . RPR card test for syphilis. 2006.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera